CSL Limited

CSL

AU000000CSL8

Pharmaceuticals

Delayed Australian S.E. 00:19:02 22/10/2026 BST			5-day change	1st Jan Change
194.97 ^AUD	-0.57%		+5.46%	+12.76%

11:22pm	Australia's CSL faces investor proceeding over disclosure obligations	RE
10-21	CSL Appoints CEO	MT

CSL Appoints CEO

Published on 10/21/2026 at 10:33 pm BST

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about CSL Limited

11:22pm	Australia's CSL faces investor proceeding over disclosure obligations	RE
10-21	CSL Appoints CEO	MT
10-21	Australia's CSL names GSK executive Waterhouse as next CEO	RE
10-20	BHP and National Australia Bank drag Aussie shares lower	RE
10-14	EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing -- Update	DJ
10-14	EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing	DJ
10-14	Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine	RE
10-08	CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform	MT
10-08	Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027	DJ
10-07	CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says	MT
10-07	ASX Midday Sector Update: Healthcare Stocks Advance, Materials Sector Struggles	MT
10-07	CSL Prices $1.5 Billion in Corporate Bonds	MT
10-06	CSL's Alentis Licensing Deal Likely to Lead to Total Addressable Market of Up to Nearly $2 Billion per Year, Jefferies Says	MT
10-05	Global markets live: Goldman Sachs, Eli Lilly, Foxconn, Accenture, BT Group…
10-05	Australian shares edge higher as CSL deal lifts healthcare stocks	RE

Gordon Naylor is Chief Executive Officer, MD & Director at CSL Ltd. since 2026.
Mr. Naylor is Independent Non-Executive Director at Orica Ltd. since 2022.
Mr. Naylor is Director at Seqirus Holdings UK Ltd. since 2015.
Mr. Naylor is Senior Vice President & General Manager at CSL Plasma, Inc. Former roles include Non-Executive Chairman at Medical Developments International Ltd. from 2020 to 2025, Chief Financial Officer at CSL Ltd. from 2010 to 2016, EVP-Plasma, Supply Chain & Information Systems at CSL Behring LLC, and President at Seqirus UK Ltd. from 2015 to 2019.
Education includes an MBA from Melbourne Business School and undergraduate studies at the University of Melbourne.

View full profile

Chart CSL Limited

Duration

Period

CSL: Dynamic Chart

Company Profile

CSL Limited is an Australia-based biotechnology company. The Companyâ€™s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâ€™s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.

Employees

29,000

Sector

Pharmaceuticals

Calendar

02-10 Earnings release - Q2 2027

More about the company